Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity.
Zepeda-Romero
L C
LC
Liera-Garcia
J A
JA
Gutiérrez-Padilla
J A
JA
Valtierra-Santiago
C I
CI
Avila-Gómez
C D
CD
Cardenas-Lamas
L J
LJ
D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005355:Fibrosis; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D012163:Retinal Detachment / Q000209:etiology / Q000601:surgery; D012171:Retinal Vessels / Q000473:pathology*; D012178:Retinopathy of Prematurity / Q000188:drug therapy*; D014821:Vitrectomy
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab